SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / MedicalMcKesson HBOC (MCK)


Previous 10 Next 10 
To: w sun who wrote (142)12/15/1999 9:03:00 AM
From: Rambi
   of 165
 
Some good news.....

biz.yahoo.com

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Rambi who wrote (143)12/15/1999 5:12:00 PM
From: Henk Wondergem
   of 165
 
NO reaction by the market yet????

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Henk Wondergem who wrote (144)12/15/1999 5:33:00 PM
From: Rambi
   of 165
 
No- and that's really discouraging. I guess everyone saw this at Yahoo:
Drug Distributors Fail to Soar on Retail Deals
By Michael Brick
TheStreet.com/NYTimes.com Staff Reporter
12/15/99 12:42 PM ET

Two pharmaceuticals distributors trumpeted new multi-year sales agreements with drugstore chains Wednesday. But the deals did little to cure the distributors' ills on Wall Street.

Bergen Brunswick, (BBC:NYSE - news), of Orange County, Calif., said it signed a five-year agreement to be New York-based Duane Reade's (DRD:NYSE - news) primary supplier of drugs and health care products. The deal is worth $200 million a year, the company said.

Separately, McKesson HBOC (MCK:NYSE - news) of San Francisco said it extended for six years a deal to serve as Youngstown, Ohio-based Phar-Mor's (PMOR:Nasdaq - news) primary supplier. That deal should generate $2 billion in revenue over its lifetime, the companies said.

Shares of Bergen gained 1/4, or 3%, to 8 1/16 by midday Wednesday, and shares of McKesson rose 1/4, or 1%, to 20 11/16. Phar-Mor shares gained 5/16, or 8%, to 2 15/16, but Duane Reade shares dropped 1/2, or 2%, to 22.

"It's nothing that I'm jumping up and down about," said Andrew Speller, analyst for A.G. Edwards. He has hold ratings on both distributors and doesn't cover the retailers. His firm co-managed a preferred stock offering for Bergen in May. "This kind of stuff happens all the time. In most other industries, people don't send out press releases when they sign supply agreements."

Both distributors have been looking for some good news this year. Bergen's stock is almost 30 points off a 52-week high of 37 3/4, and McKesson's is almost 70 points off a 52-week high of 89 3/4.

For McKesson, the deal with Phar-Mor may prove slightly more substantive than its previous arrangement with the retailer because it includes automation products, Speller said. The products -- with names like OmniLink and BakerAPS Pharmacy 2000 -- count pills and notify pharmacists if a patient's insurance won't pay for the drug his doctor prescribed.

That could increase profits at Phar-Mor by allowing the company to eliminate technicians, and the products carry a higher profit margin for McKesson, according to Speller.

"This is pretty much prototypical of what the wholesalers are trying to do," Speller said. "You make money selling pharmaceuticals on the wholesale side, but you make a lot more money offering these other services."

Share RecommendKeepReplyMark as Last Read


To: Rob Pierce who wrote ()1/11/2000 10:24:00 AM
From: Paul Lee
   of 165
 
McKesson HBOC, Inc., Signs Definitive Agreement to Sell Its Water Products Business to Groupe DANONE for $1.1 Billion
SAN FRANCISCO--(BUSINESS WIRE)--Jan. 11, 2000--McKesson HBOC, Inc. (NYSE:MCK - news; McKessonHBOC) announced today that it has signed a definitive agreement with the Groupe DANONE (NYSE:DA - news) whereby DANONE will purchase the McKesson Water Products Company, a subsidiary of McKessonHBOC, for a total consideration of $1.1 billion in cash.

The transaction has been approved by the Boards of Directors of both companies and is subject to regulatory review and other customary conditions.

The McKesson Water Products Company is the third-largest processor, marketer and distributor of bottled water in the United States. The company markets bottled water in 30 states under the Sparkletts©, Alhambra© and Crystal(TM) brands. McKesson Water Products has expected revenues of more than $380 million with an EBITDA margin of 22% in its fiscal year ended March 31, 1999.

``Given our strategic focus on improving healthcare quality and cost through our market-leading positions in healthcare information technology and supply management, McKesson Water Products was not a core business,' said John H. Hammergren and David L. Mahoney, McKessonHBOC co-presidents and co-chief executive officers.

``We believe that this transaction is in the best interests of both our shareholders and the Water Products Company employees who have created significant value in this business. We wish them well as they become a key element of DANONE's U.S. bottled water business

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Paul Lee who wrote (146)1/11/2000 10:26:00 AM
From: epicure
   of 165
 
Seems like a good move so far.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: epicure who wrote (147)1/11/2000 11:16:00 AM
From: J L Segal
   of 165
 
Anyone else expecting a short squeeze here? The last report showed nearly 12MM shares short in MCK. That's a lot of covering to do -soon, IMO - considering the latest news plus upgrades from Lehman & ML, and insider buying.

JL

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: J L Segal who wrote (148)1/11/2000 11:29:00 AM
From: epicure
   of 165
 
OOOH- I wasn't expecting one, but I'll be mighty happy if we get one.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: epicure who wrote (149)1/31/2000 5:52:00 PM
From: Mort
   of 165
 
McKessonHBOC Completes Acquisition of Prospective Health, Inc., Leading Healthcare Software Developer
Monday, January 31, 2000 08:10 AM
PALOS HEIGHTS, Ill.--(BUSINESS WIRE)--Jan. 31, 2000--McKesson HBOC, Inc. (McKessonHBOC) (NYSE:MCK, news, msgs), the world's leading supply management and healthcare information technology company, announced today that is has completed its acquisition of Palos Heights, Illinois-based Prospective Health, Inc., a privately held developer of integrated software solutions for the healthcare industry. Financial terms of the full acquisition were not disclosed.
The company made an initial investment in the company in 1995 when PHI was selected to provide software for McKessonHBOC's OmniLink(R) pre- and post-adjudication system for third-party prescriptions.

PHI will operate as a separate company under the direction of Tom George, President of McKessonHBOC's Customer Technology Group. Michael Gremillion and David D'Altorio continue to serve as PHI's Executive Vice President and General Manager, and Senior Vice President of Sales and Marketing respectively.

"Over the past four years, as OmniLink expanded to include a wide range of independent and chain pharmacies we recognized the strategic value of PHI to our Supply Management Business," commented Tom George. "PHI provides healthcare management software to customers in a wide range of benefits management areas including vision, dental and prescription medications, as well as communications networks and data warehousing. With existing software products and a solid customer base in these industry segments, PHI is expected to be a key player in the emerging e-health initiative," he added, "and we took the necessary steps to make PHI and integral part of McKessonHBOC."

McKessonHBOC, Inc., a Fortune 100 corporation, provides pharmaceutical supply management and healthcare information technologies across the entire continuum of healthcare, including market-leading businesses in pharmaceutical and medical surgical distribution, information technology for health care providers, services for payors and outsourcing. McKessonHBOC is located at One Post Street, San Francisco, California, 94104. More information about McKessonHBOC is available at mckhboc.com.

Based near Chicago in Palos Heights, IL, PHI has nearly 50 employees in its offices in Palos Heights, Scottsdale, Arizona and Kansas City, Kansas, and has sales teams in Irvine and San Diego, California. Prospective Health is a leading software development company that designs, develops, consults, and installs software solutions for the healthcare industry. Designed to meet the demanding requirements of online, real-time transaction processing and relational database management, PHI systems, ProPBM(TM), ProINTERCEPT(TM), ProHEALTHi(TM) and ProDENTAL, provide centralized claim editing, adjudication and data control related to pharmacy, medical and dental transactions, and are available to the marketplace in a license or service bureau arrangement. More information about Prospective Health, Inc. is available at prospective-health.com.


Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Mort who wrote (150)2/1/2000 8:29:00 AM
From: Wally Mastroly
   of 165
 
Some MCK headlines this morning (Edit adds the article):

07:52 [MCK] MCKESSON HBOC SAYS ARROW CONTRACT WORTH $1 BILLION IN REVENUE

07:52 [MCK] MCKESSON HBOC EXTENDS PHARMACEUTICAL SUPPLY AGREEMENT WITH ARROW

biz.yahoo.com

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Wally Mastroly who wrote (151)2/22/2000 10:40:00 AM
From: Mort
   of 165
 
Somebody has faith in MCK

February 16, 2000 07:02 PM
WASHINGTON, Feb 16 (Reuters) - David Geffen, one of the three leaders at Hollywood film studio DreamWorks, said on Wednesday he acquired a stake currently worth more than $278 million in McKesson HBOC Inc.MCK , the largest U.S. drug distributor.

Geffen, who heads DreamWorks with Hollywood heavyweights Steven Spielberg and Jeffrey Katzenberg, acquired 5 percent, or 14,087,700 common shares, for general investment purposes, according to a filing with the U.S. Securities and Exchange Commission.

Using his personal funds, Geffen bought shares of San Francisco-based McKesson between Dec. 13 and Feb. 11 at prices ranging from $18.8750-$22.6250 a share.

The largest one-day purchase during that period were 1 million shares on Jan. 25 for $22.50 each, and an additional 1 million shares bought two days later at $20.9375 each.

Geffen disclosed his stake in the company because of SEC rules that say anyone holding a stake of 5 percent or more in a company must publicly report their holdings.


Share RecommendKeepReplyMark as Last ReadRead Replies (1)
Previous 10 Next 10